お知らせ • Apr 21
PeptiDream Inc. Announces Initiation Of Phase 1 Clinical Trial Of AK1940 by its Collaboration Partner Asahi Kasei Therapeutics PeptiDream Inc. announced that Asahi Kasei Therapeutics its collaboration partner, has initiated a Phase 1 clinical trial1 of “AK1940”, a selective inhibitor of TNF receptor 1 (“TNFR1”). AK1940 is a macrocyclic peptide discovered through a research collaboration between the two companies using PeptiDream’s proprietary Peptide Discovery Platform System (PDPS®)2. AK1940 showed potent inhibitory activity and high selectivity for TNFR1 and exhibited efficacy in animal models of inflammatory disease, supporting its potential for the treatment of a broad range of autoimmune diseases. PeptiDream and Asahi Kasei Therapeutics entered into a collaborative research and development agreement in March 2016, under which the two companies have advanced the discovery of macrocyclic peptides using PeptiDream’s PDPS® technology. Asahi Kasei Therapeutics focuses its drug discovery and development efforts on disease areas including autoimmune diseases, severe infections, transplantation, kidney diseases, and orthopedic conditions. AK1940 is well aligned with Asahi Kasei Therapeutics’ R&D strategy and is expected to contribute to the medium- to long-term growth of the company’s pharmaceuticals business. With the initiation of the Phase 1 trial, PeptiDream will receive a milestone payment (amount undisclosed). Furthermore, PeptiDream is entitled to receive future clinical milestone payments, as well as royalties based on sales after launch. お知らせ • Mar 23
PeptiDream Inc.(TSE:4587) dropped from FTSE All-World Index (USD) PeptiDream Inc.(TSE:4587) dropped from FTSE All-World Index (USD) お知らせ • Dec 18
PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis PeptiDream Inc. announced its second oral peptide therapeutic program entering into its Clinical Development Portfolio - a dual IL-17A and IL-17F macrocyclic peptide inhibitor targeting the major dimeric forms of interleukin-17 (IL-17AA, IL-17AF, IL-17FF) - at their 2025 R&D Day held on December 5, 2025. The development candidate demonstrated biologic-like efficacy in preclinical models when orally administered, aiming to deliver a deeper and more durable response across skin and musculoskeletal manifestations, improving patient quality of life. The IL17 pathway is a clinically validated therapeutic target across several major autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. Although today's approved IL17 inhibitors deliver excellent clinical outcomes, all are injectable biologics, which can limit convenience and long-term accessibility. PeptiDream's oral IL17 macrocyclic peptide is designed to change this paradigm--offering the potential for biologiclike efficacy with the benefits of oral administration, as well as the versatility for monotherapy or combination therapy with TNF or JAK inhibitors, providing new options for patients with difficulttotreat disease. Key Highlights of the Program: Potent Orally Bioavailable Macrocyclic Peptide: Engineered for high-affinity and stability to achieve oral bioavailability and biologic-like potency. Inhibits Critical IL-17 Isoforms: Designed to inhibit not only IL-17A/A, IL-17A/F, but also IL-17F/F, associated with deeper and more durable clinical responses. Enhanced Tissue Penetration: The macrocyclic peptide candidate's small size enables improved distribution and potential for superior tissue-localized activity. Broad Therapeutic Opportunity: An oral therapy with the potential to treat a broad range of IL17-mediated diseases, unlocking new monotherapy and combination therapy approaches. PeptiDream's Oral dual IL-17A andIL-17F inhibitor was discovered using its proprietary PDPS®? technology and optimized for potency and oral bioavailability. In an IL-17 in vivo challenge model, oral dosing of peptide significantly reduced CXCL1 levels to the same extent as IV administration of an approved IL-17 biologic. Notably, greater skin distribution versus plasma was observed at 24 hours--a key differentiator over current biologics. Building on these encouraging results, PeptiDream is advancing the program into IND-enabling studies with a view toward clinical trials, while exploring strategic partnerships to accelerate global development and deliver a best-in-class oral therapy for autoimmune disease patients worldwide. お知らせ • Dec 03
PeptiDream Inc. to Report Fiscal Year 2025 Results on Feb 16, 2026 PeptiDream Inc. announced that they will report fiscal year 2025 results on Feb 16, 2026 お知らせ • Oct 15
PeptiDream, PDRadiopharma and Curium Group Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA- I&T for Prostate Cancer in Japan PeptiDream Inc., PDRadiopharma Inc. and Curium Group announced that a registrational Phase 2 clinical trial has been initiated in Japan for 64Cu-PSMA-I&T, a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells. 64Cu-PSMA- I&T is being assessed as a diagnostic PET imaging agent labeled with the radioisotope Copper-64, being developed with its therapeutic pair, 177Lu-PSMA-I &T. The development is conducted under the strategic collaboration between PDRadiopharma and Curium aiming at advancing innovative radiopharmaceuticals for prostate cancer in Japan. The open-label, single-arm Phase 2 study will evaluate the sensitivity, specificity, and safety of 64Cu-PSMA- me&T. The trial will enroll approximately 70 patients who have been newly diagnosed with unfavorable intermediate, high or very high-risk prostate cancer and are scheduled for prostatectomy with pelvic lymph node dissection. This study is being conducted as a registrational trial in Japan and will utilize bridging data from Curium's ongoing global clinical trials. In parallel, a clinical trial for 177Lu-PSMA- I& T as a therapeutic agent is being planned to evaluate its efficacy and safety in patients with metastatic castration-resistant prostate cancer (mCRPC). お知らせ • Sep 27
PeptiDream Inc. to Report Q3, 2025 Results on Nov 12, 2025 PeptiDream Inc. announced that they will report Q3, 2025 results on Nov 12, 2025 お知らせ • May 31
PeptiDream Inc. to Report Q2, 2025 Results on Aug 06, 2025 PeptiDream Inc. announced that they will report Q2, 2025 results on Aug 06, 2025 お知らせ • Mar 30
National Cancer Center Hospital East and PeptiDream Inc. Announces New Radiopharmaceuticals for Renal Cell Carcinoma National Cancer Center Hospital East and PeptiDream Inc. announced promising results from the first-in-human imaging trial of 64Cu-PD-32766, a 64Cu-labelled radiopharmaceutical targeting Carbonic Anhydrase IX (CA9), for patients with clear cell renal cell carcinoma (ccRCC). This trial, which was conducted at the NCC Hospital East in collaboration started from November 2023, aims for the early application of radiopharmaceuticals targeting CA9. The results showed that 64Cu-PD-327 66 effectively diagnosed tumors and in addition, calculations replacing 64Cu with 225Ac suggest that the absorbed dose in the tumor was 105.5+-55.8 mGy/MBq, which is expected to be sufficient for therapeutic effect. These findings were presented at the ASCO Genitourinary Cancers Symposium 2025 held in February 2025. In this trial, Cu-PD-32766, which was manufactured using NCC Hospital’s Cu production technologies and EPOC’s radiopharmaceuticals manufacturing technologies, was administered to five patients with newly diagnosed, relapsed or suspected relapsed ccRCC at NCC Hospital East. The safety, pharmacokinetics and dosimetry of PET/CT imaging using Cu-PD-32766 were evaluated. The effective dose for whole body by administration of Cu-PD-32766 was 0.102±0.0361 mSv/MBq and no serious side effects or adverse events were observed. Accumulation of Cu-PD-32766 in tumor lesions was confirmed by PET imaging within 5 minutes after administration, with positive rate of over 95% of lesions diagnosed by CT imaging. Clear PET images of tumor lesions were obtained from 5 minutes to 24 hours post-administration. The blood concentration of Cu-PD-32766 rapidly decreased within 5 minutes after administration, confirming good clearance.
These results suggest the potential utility of Cu-PD-32766 as a diagnostic agent for ccRCC. Furthermore, calculations replacing Cu with the therapeutic radionuclide Ac suggest that the absorbed dose in the tumor was 105.5±55.8 mGy/MBq, which is expected to be sufficient for therapeutic effects. This trial investigated the potential application of Cu-PD-32766 as a diagnostic agent by evaluating safety, pharmacokinetics and whole-body absorbed dose. The results also suggest the potential theranostic application of PD-32766 by using both diagnostic and therapeutic radionuclides such as Ac. By evaluating the pharmacokinetics and targeted accumulation in tumors with a minimal dose administered to patients, this trial is anticipated to contribute to accelerating subsequent clinical development of PD-32766. CA9 is a cell surface antigen highly expressed in ~95% of ccRCC with minimal expression in normal tissues, making it a potentially ideal target for the diagnosis and treatment of ccRCC. PeptiDream discovered and developed PD-32766 using its proprietary Peptide Discovery Platform System (PDPS) technology, with in vivo imaging and efficacy studies conducted by PDRadiopharma Inc., PeptiDream’s wholly owned subsidiary. お知らせ • Feb 13
PeptiDream Inc., Annual General Meeting, Mar 27, 2025 PeptiDream Inc., Annual General Meeting, Mar 27, 2025. お知らせ • Dec 12
PeptiDream Inc. Announces Second Internal Peptide Radiopharmaceutical Therapeutic Program Targeting Claudin 18.2 for the Potential Diagnosis and Treatment of Gastric Cancer PeptiDream Inc. announced its second wholly-owned radiopharmaceutical development candidate arising from the company's ongoing internal peptide radiopharmaceutical discovery and development efforts. The development candidate ("PD-29875") is a novel first-in-class highly-selective macrocyclic peptide-radioisotope (RI) conjugate against Claudin 18.2 ("CLDN18.2"), a member of the claudin family of proteins that are integral components of tight junctions found in epithelial tissues. CLDN18.2 is expressed in a variety of solid tumors, including gastric cancer, pancreatic cancer, biliary cancer, genitourinary tract cancers, and colorectal cancer, and others. PD-29875 was discovered using PeptiDream's proprietary PDPS technology and further optimized at PeptiDream with in vivo imaging and efficacy studies conducted at PDRadiopharma, wholly owned subsidiary. PeptiDream has initiated IND-enabling studies of PD-29875 and intends to initially develop the therapeutic (225Ac-PD-29875) and paired diagnostic imaging agent (64Cu-PD-29875) for the diagnosis and treatment of gastric cancer. The paired diagnostic imaging agent, which consists of the same peptide and chelator as the therapeutic, will enable to screen and identify patients, both in clinical trials and in clinical practice, who have CLDN18.2 expressing tumors that are most likely to have a favorable clinical response from PD-29875 treatment. PeptiDream is previously planning to initiate human Ph0 imaging studies of 64Cu-PD-29875 in 2025, prior to the start of a Phase 1 study. Gastric cancer is the 5th most common cancer in and the 4th leading cause of cancer death worldwide in 2020, representing 7% of all global cancer diagnoses, with an approximate 5-year survival rate of 32% (worldwide an estimated 1.1 million people were diagnosed with gastric cancer in 2020, with 770,000 deaths), with the incidence expected to increase to 1.8 million new cases per year by 2040. お知らせ • Dec 03
PeptiDream Inc. to Report Fiscal Year 2024 Results on Feb 13, 2025 PeptiDream Inc. announced that they will report fiscal year 2024 results on Feb 13, 2025 お知らせ • Nov 12
PeptiDream Inc. (TSE:4587) acquired an additional unknown stake in PeptiStar Inc. from INCJ, Ltd. PeptiDream Inc. (TSE:4587) acquired an additional unknown stake in PeptiStar Inc. from INCJ, Ltd. on November 11, 2024.
PeptiDream Inc. (TSE:4587) completed the acquisition of an additional unknown stake in PeptiStar Inc. from INCJ, Ltd. on November 11, 2024. お知らせ • Aug 28
PeptiDream Inc. to Report Q3, 2024 Results on Nov 13, 2024 PeptiDream Inc. announced that they will report Q3, 2024 results on Nov 13, 2024 お知らせ • Jun 05
National Cancer Center and PeptiDream Announces the First Dosing of Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma The National Cancer Center Hospital East and PeptiDream Inc. announced the dosing of the first patient in the human imaging study of PeptiDream’s 64Cu-PD-32766, a 64Cu-labelled radiopharmaceutical targeting Carbonic Anhydrase IX (CAIX), for patients with clear cell renal cell carcinoma (ccRCC) conducted at the National Cancer Center Hospital East. The clinical research, which was approved by the National Cancer Center Japan’s clinical review board in April 2024, is a first-in-human imaging study of 64Cu-PD-32766 conducted in collaboration with the National Cancer Center Japan and PeptiDream. This study is intended to evaluate the safety, pharmacokinetics, and accumulation of 64Cu-PD-32766 in tumors using PET in patients with newly diagnosed, relapsed or suspected relapsed ccRCC. CAIX is a cell surface antigen highly expressed in ~95% of ccRCC with minimal expression in normal tissues, making it a potentially ideal target for the diagnosis and treatment of ccRCC. PeptiDream discovered and developed PD-32766 using its proprietary Peptide Discovery Platform System (PDPS) technology, with in vivo imaging and efficacy studies conducted by PDRadiopharma Inc. (PeptiDream’s wholly owned subsidiary). Key advantages of this clinical research are the ability to generate early human imaging data (often referred to as a Phase 0 study) using diagnostic 64Cu agent directly in the target patient population which provides an early look at the diagnostic usefulness of the agent, the likelihood of therapeutic benefit when labeled with a therapeutic radioisotope, and additional critical information that can be used in designing subsequent clinical studies, thereby significantly accelerating clinical development. お知らせ • Jun 02
PeptiDream Inc. to Report Q2, 2024 Results on Aug 08, 2024 PeptiDream Inc. announced that they will report Q2, 2024 results on Aug 08, 2024 お知らせ • Feb 28
PeptiDream Inc. to Report Q1, 2024 Results on May 14, 2024 PeptiDream Inc. announced that they will report Q1, 2024 results on May 14, 2024 お知らせ • Feb 14
PeptiDream Inc., Annual General Meeting, Mar 27, 2024 PeptiDream Inc., Annual General Meeting, Mar 27, 2024. お知らせ • Dec 17
PeptiDream Inc. to Report Fiscal Year 2023 Results on Feb 14, 2024 PeptiDream Inc. announced that they will report fiscal year 2023 results on Feb 14, 2024 お知らせ • Aug 27
PeptiDream Inc. to Report Q3, 2023 Results on Nov 09, 2023 PeptiDream Inc. announced that they will report Q3, 2023 results on Nov 09, 2023 お知らせ • May 28
PeptiDream Inc. to Report Q2, 2023 Results on Aug 09, 2023 PeptiDream Inc. announced that they will report Q2, 2023 results on Aug 09, 2023 お知らせ • May 12
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023 PeptiDream Inc. provided consolidated earnings guidance for the year ending December 31, 2023. For the year, the company expects revenue to be JPY 30,000 million, Operating profit to be JPY 6,300 million, Profit attributable to owners of parent to be JPY 2,700 million. お知らせ • Feb 15
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023 PeptiDream Inc. provided consolidated earnings guidance for the fiscal year ending December 31, 2023. For the year, the company expects revenue of JPY 30,000 million, operating profit of JPY 6,300 million and profit attributable to owners of parent of JPY 2,700 million. お知らせ • Feb 14
PeptiDream Inc., Annual General Meeting, Mar 29, 2023 PeptiDream Inc., Annual General Meeting, Mar 29, 2023. お知らせ • Dec 14
PeptiDream Inc. to Report Q4, 2022 Results on Feb 14, 2023 PeptiDream Inc. announced that they will report Q4, 2022 results on Feb 14, 2023 お知らせ • Mar 06
PeptiDream Inc. to Report Q2, 2021 Results on Aug 05, 2021 PeptiDream Inc. announced that they will report Q2, 2021 results on Aug 05, 2021 お知らせ • Mar 02
PeptiDream Inc. Announces Licensing of Automated PDPS Platform to Ono Pharmaceutical Co., Ltd PeptiDream Inc. announced that it has entered into a Technology License Agreement with Ono Pharmaceutical Co. Ltd., to non-exclusively license PeptiDream's proprietary automated Peptide Discovery Platform System (PDPS) technology platform to ONO. Under the terms of the agreement, PeptiDream will receive an undisclosed upfront payment, as well as be eligible for certain payments based on achievement of certain predetermined development milestones for any constrained peptides and/or small molecules discovered from use of the automated PDPS technology platform. In addition, PeptiDream is eligible to receive royalties on sales of certain products that arise from use of the automated PDPS technology platform. Similar to previous technology license agreements, work on peptide-drug conjugates (PDCs) is excluded from the non-exclusive license. High-affinity peptides will be identified through the use of the automated PDPS technology platform for new drug targets that have been suggested to be associated with specific diseases. ONO will also leverage the information obtained through the process, aiming to discover and develop innovative new drugs in a short period of time with high success rate. お知らせ • Dec 23
PeptiDream and Takeda Enter into Collaborative Research and Exclusive License Agreement to Develop Peptide Drug Conjugates for Neuromuscular Disease PeptiDream Inc. and Takeda Pharmaceutical Company Limited announced that they have agreed to a collaborative research and exclusive license agreement to create peptide-drug conjugates (PDCs) for neuromuscular diseases.
Despite advances in the under standing of neuromuscular diseases, the broad biodistribution required to target key tissues throughout the body that contribute to disease remains a key chal enge for drug development. The
agreement aims to address these challenges by conjugating peptides developed by PeptiDream and JCR Pharmaceuticals Co. Ltd. that bind to the transferrin receptor to specific drug payloads selected by Takeda to improve their profile of tissue distribution for treating neuromuscular diseases. Under the terms of the agreement, PeptiDream will receive an upfront payment from Takeda. PeptiDream may also receive milestone payments based on the achievements of specified pre-clinical research and clinical trial achievements. お知らせ • Dec 10
PeptiDream Announces Strategic Partnership and License Option Agreement with Amolyt Pharma PeptiDream Inc. announced that it has entered into a strategic partnership and license option agreement with Lyon, FRANCE-based Amolyt Pharma ("Amolyt"), whereby both companies will work together to test and further optimize PeptiDream's Growth Hormone Receptor Antagonist "GHRA" peptide candidates, with the goal of selecting a clinical candidate for development in acromegaly, a rare endocrine disorder with serious medical complications, to which Amolyt has an option to license the candidates for future clinical development. Under the terms of the agreement, PeptiDream will be eligible for certain payments associated with the licensing, development, and commercial success of any GHRA product(s), as well as be eligible for certain royalties on future net sales. お知らせ • Dec 05
PeptiDream Inc. to Report Fiscal Year 2020 Results on Feb 10, 2021 PeptiDream Inc. announced that they will report fiscal year 2020 results on Feb 10, 2021 お知らせ • Sep 04
PeptiDream Inc. to Report Q3, 2020 Results on Nov 12, 2020 PeptiDream Inc. announced that they will report Q3, 2020 results on Nov 12, 2020 お知らせ • Aug 09
PeptiDream Inc. to Report Q2, 2020 Results on Aug 06, 2020 PeptiDream Inc. announced that they will report Q2, 2020 results on Aug 06, 2020